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Allergies are a result of allergen proteins cross-linking allergen-
specific IgE (sIgE) on the surface of mast cells and basophils. The
diversity and complexity of allergen epitopes, and high-affinity of the
sIgE–allergen interaction have impaired the development of allergen-
specific inhibitors of allergic responses. This study presents a design of
food allergen-specific sIgE inhibitors named covalent heterobivalent
inhibitors (cHBIs) that selectively form covalent bonds to only sIgEs,
thereby permanently inhibiting them. Using screening reagents
termed nanoallergens, we identified two immunodominant epitopes
in peanuts that were common in a population of 16 allergic patients.
Two cHBIs designed to inhibit only these two epitopes completely
abrogated the allergic response in 14 of the 16 patients in an in vitro
assay and inhibited basophil activation in an allergic patient ex vivo
analysis. The efficacy of the cHBI design has valuable clinical implica-
tions for many allergen-specific responses and more broadly for any
antibody-based disease.
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Allergy symptoms can vary from a rash to a potentially fatalanaphylactic reaction. Food allergies, especially peanut
allergy, fall into the latter. These types of allergic reactions (IgE-
dependent type-I hypersensitivity reactions) can lead to life-
threatening systemic inflammatory responses such as anaphylactic
shock (1, 2). The critical step in a peanut-allergy reaction is the
binding of peanut allergens to allergen-specific IgE antibodies
(sIgEs) attached to the high-affinity Fc epsilon receptors (FceRIs)
on mast cell surfaces that results in their cross-linking. This cross-
linking triggers intracellular signaling that culminates in cellular
degranulation that releases preformed mediators stored in cyto-
plasmic granules, including vasoactive amines, neutral proteases,
proteoglycans, cytokines, and chemokines (3).
Currently, in the clinic, there are no medications that can prevent
the degranulation response from mast cells, aside from a nonspecific
IgE depletion therapy, wherein omalizumab, a monoclonal antibody,
binds and inhibits all IgE from binding the surface receptor. Although
it has shown effectiveness in clinical treatment of asthma, omalizu-
mab has not been approved for the treatment of peanut allergies (4,
5). Furthermore, the inhibition of all IgE can lead to nonspecific
immune suppression, leading to increases in parasitic infection and
cancer (6, 7). A targeted and specific sIgE inhibitor would alleviate
these concerns. One strategy for inhibition of peanut-allergy reactions
(and any other food allergy) is to prevent the binding of allergen
epitopes to sIgEs, but there are currently no functional examples of
specific sIgE inhibitory compounds in the clinic or scientific literature.
The major challenge in developing targeted sIgE inhibitors is
to identify the critical immunogenic epitopes from the large
number of potential epitopes on allergen proteins (8, 9). Liter-
ature reports of several sIgE binding epitopes of the two most
immunogenic peanut proteins, Ara h 2 and Ara h 6, exist (10,
11). These studies, however, did not assess the relative impor-
tance of those epitopes for IgE-dependent activation, instead
only determining that they bind sIgEs. Here, we developed a
physiologically relevant, nanoparticle-based assay system we
termed nanoallergens, to identify the most critical immunogenic
epitopes of Ara h 2 and Ara h 6. Next, we used this information
to rationally design a class of sIgEs inhibitors, named covalent
heterobivalent inhibitors (cHBIs), to irreversibly bind to and
inhibit peanut allergen/sIgE interactions, thereby selectively and
exhaustively inhibiting peanut-allergy reactions (SI Appendix,
Fig. S1). We demonstrated, by using peanut allergic patient sera,
that cHBIs specifically and irreversibly target the most crucial
sIgEs for allergic responses and yield almost complete inhibition
of degranulation responses to peanuts in cellular assays with
patient serum. This study presents compelling preclinical data
for further development and assessment of the cHBI strategy as
inhibitors of peanut allergies and other food allergies to improve
patient outcomes.
Results
Identification of Immunodominant Ara h 2 and Ara h 6 Epitopes Using
the Nanoallergen Assay. To facilitate design of cHBIs, we first
identified the most critical immunogenic epitopes from Ara h
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2 and Ara h 6 using the nanoallergen assay system developed in
our laboratory (12). Nanoallergens provide multivalent display for
allergen epitopes on liposomal surfaces, which are then used to
evaluate their immunogenicity via in vitro mast cell degranulation
responses (Fig. 1A). Currently used microarray techniques only
determine if IgE binds a particular epitope but lack proper epitope
display and valency to trigger cellular degranulation (13). Nano-
allergens overcome these shortcomings and provide a physiologi-
cally relevant assay system to evaluate immunogenicity of epitopes
by directly comparing cellular responses not just relative binding.
Nanoallergen preparation required synthesis of epitope-lipids,
for which potential epitopes (synthesized as linear peptides) are
conjugated to palmitic acid tails via ethylene glycol (EG). The
epitope-lipid was purified, mixed at precise ratios with phospholipids
[1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)] and extruded
through membranes to form 100-nm nanoparticles (SI Appendix,
Fig. S2). These nanoallergens multivalently present epitopes on their
surfaces with high-precision and controlled stoichiometry (12, 14).
Nanoallergens were used to trigger degranulation response in RBL-
SX38 cells [model mast cell line which expresses human IgE re-
ceptor (FceRI)] (15) primed with a specific patient serum (Fig. 1A).
This assay enables patient-specific assessment of epitope immuno-
genicity, rather than only assessing binding interactions, and hence
accurately identifies the most allergenic epitopes.
We synthesized nanoallergens which present epitopes for
10 commonly cited peanut protein epitopes in the literature,
epitopes 1–5 of Ara h 2, and epitopes 1–5 of Ara h 6 (SI Appendix,
Table S1) (10, 11, 16–18). To evaluate these epitopes, we used
human serum from 16 peanut-allergic patients obtained from
PlasmaLabs and Massachusetts General Hospital (SI Appendix,
Table S2). Serum samples were selected based on clinical history
of peanut-allergic responses (as verified by commercial source or
by food challenge) and a peanut sIgE >50 kU/L as determined by
ImmunoCAP (SI Appendix, Table S2). Serum from each patient was
used to prime RBL-SX38 cells before incubation with nanoallergens
(0–5 nM) presenting each of the epitopes (SI Appendix, Fig. S3).
Degranulation was monitored via beta-hexosaminidase assay and
EC50 values were determined (Table 1 and SI Appendix, Table S3).
Our results identified Ara h 2 epitope 5, and Ara h 6 epitope 5 to be
immunodominant, given their low EC50 (EC50 < 10 pM for Ara h
2 epitope 5 and EC50 < 100 pM for Ara h 6 epitope 5) for most
patient samples. Note that as demonstrated previously (12), de-
granulation intensity does not correlate with epitope dominance due
to inhibitory cascades [such as Src homology 2 (SH2) domain con-
taining inositol polyphosphate 5-phosphatase 1 (SHIP)] that attenuate
degranulation (19). Hence, EC50 values were used as the primary
metric for epitope dominance.
Identification of Potentially Cross-Reactive Peanut Protein Epitopes
via Analysis of Epitope Sequence Homology. The major challenge of
preventing allergic reactions with sIgE inhibitors is the large
number of epitopes on allergy proteins that could bind to a di-
verse set of sIgEs (20). In peanuts, among the 13 known im-
munogenic proteins, Ara h 2 and Ara h 6 are the immunogenic
proteins most closely associated with severe allergic reactions
(21). Other proteins such as Ara h 1 and Ara h 3, however, are
also immunogenic, albeit triggering less severe reactions (21).
While it is not practical to develop inhibitors for each epitope/
sIgE interaction, it is known that allergens often have homolo-
gous epitopes between two different proteins, and sIgEs can be
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Fig. 1. cHBIs are designed to selectively and irreversibly bind sIgEs and inhibit cellular degranulation. (A) Cartoon demonstration of the nanoallergen assay
system for evaluating potential immunogenic epitopes. Potential epitopes of allergen proteins are synthesized as linear peptides conjugated to lipid tails
(epitope-lipid). Epitope-lipids are then incorporated during liposome synthesis to produce nanoallergens. Nanoallergens are used to screen for epitope
immunogenicity in cellular degranulation assays. (B) cHBI design. cHBIs were synthesized to display an immunogenic epitope that binds to the ABS of sIgEs, a
NBS ligand that binds to the NBS of sIgEs, and an amine/lysine-reactive moiety (ITC) to facilitate irreversible binding to sIgEs. Representative crystal structure
of an Ig with the ABS, NBS (orange), and a lysine proximal to NBS (black) is shown. The zoomed-in Fab region describes cHBI’s bivalent NBS and ABS binding,
which promotes covalent conjugation to the proximal lysine. (C) Chemical structure of cHBI. The immunodominant epitope, NBS ligand, and ITC moiety are
linked using flexible EG linkers to facilitate bivalent binding and covalent bond formation to sIgEs. (D) Schematic illustration of allergy inhibition by cHBIs.
After initial bivalent binding to ABS and NBS, cHBI forms a covalent bond with sIgEs via ITC cross-linking of the nearby lysine, thereby inhibiting cellular
degranulation.
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potentially designed to have cross-reactivity for several allergenic
proteins simultaneously (17, 22). We noticed a high level (>50%)
of homology between the most immunogenic epitopes identified
in our nanoallergen analysis, Ara h 2 epitope 5 and Ara h
6 epitope 5, and epitopes from Ara h 1, Ara h 2, Ara h 3, and Ara
h 6 (SI Appendix, Table S4). Hence, we hypothesized that by
developing inhibitors of immunodominant epitope/sIgE inter-
actions, namely Ara h 2 epitope 5 and Ara h 6 epitope 5, we
could inhibit epitope/sIgE interactions for a broad range of im-
munogenic epitopes because of homology and possible cross-
reactivity with sIgEs and improve the therapeutic potential of
cHBI.
Rational Design and Synthesis of cHBIs to Inhibit Binding of sIgEs to
Immunodominant Allergy Epitopes. Next, we engineered cHBIs
that irreversibly inhibit binding of sIgEs to these two immuno-
dominant epitopes. The cHBI design required three moieties
linked by ethylene-glycol spacers: (i) the immunodominant epi-
topes from Ara h 2 and Ara h 6 to target the antigen binding site
(ABS), (ii) a ligand to target the nucleotide binding site (NBS),
and (iii) a reactive functional group (RFG) to form a covalent
bond with target sIgEs (Fig. 1 B and C). NBS is a conserved
binding site located proximal to the ABS between the heavy and
light chains of all immunoglobulins (Fig. 1B) (23, 24). We
identified a molecule, indole-3 butyric acid (IBA) that specifi-
cally binds to NBS with moderate affinity (Kd = 2–10 μM) (23,
25, 26). Targeting two independent sites on sIgEs simulta-
neously, ABS (with a peptide epitope) and NBS (with IBA),
enables cHBIs to have both increased avidity and selectivity for
target sIgEs. The moderate affinity of IBA minimizes its binding
to off-target antibodies and requires an ABS ligand for effective
inhibition, while the bivalent binding to both sites improves
overall avidity and selectivity for sIgEs (23). The third critical
design factor for cHBIs is the RFG which facilitates covalent
bond formation after a cHBI binds bivalently to target sIgEs,
thereby permanently inhibiting sIgE/allergen interaction. For
this purpose, we chose an amine-reactive moiety, isothiocynate
(ITC), as the RFG in the design of cHBIs (Fig. 1C). ITC com-
pounds are common in nature and are nontoxic (27). ITC groups
form thiourea bonds with primary amines, such as lysines, in
elevated pH solutions (>9) but have limited reactivity at pH 7.4
(t1/2 > 50 h) (28). Consequently, under physiological conditions,
ITC has negligible reactivity with random lysines, reducing off-
target conjugations with other serum proteins. Furthermore, this
limited reactivity means the preassociation of cHBIs with an
ABS/NBS is necessary to enhance the kinetics of covalent bond
formation on sIgEs via increased ITC effective molarity, thereby
providing selectivity. We previously confirmed that the NBS
pocket is highly conserved in antibodies by analyzing over
260 antibody crystal structures (29) and have identified a lysine
within 2 nm of the NBS pocket lip on several antibody crystal
structures (SI Appendix, Fig. S4). This lysine provided the po-
tential reactive site on sIgE Fab for the irreversible conjugation
of cHBIs, thus enabling selective and irreversible inhibition of
allergic reactions (Fig. 1D).
We synthesized two versions of cHBIs displaying Ara h 2 epi-
tope 5 (cHBIArah2/ep5) or Ara h 6 epitope 5 (cHBIArah6/ep5) using
Fmoc solid-phase peptide synthesis (SI Appendix, Fig. S5). ITC
on cHBI was stable at pH 7.4, but became reactive at pH 10.0,
indicating that cHBIs will have negligible off-target conjugation
at pH 7.4 (SI Appendix, Fig. S6). We also synthesized fluorescein-
tagged cHBIs which were used to detect cHBI binding to sIgEs
(Table 2). Note that a 1:1 combination of cHBIArah2/ep5:
cHBIArah6/ep5 (which will be referred to as cHBIArah2:Arah6) was
used for all following experiments unless otherwise noted.
cHBIs Selectively Bind to Peanut sIgEs in Clinically Relevant Patient
Serum Samples. To determine if cHBIArah2:Arah6 binds specifically to
sIgEs in clinically relevant patient serum samples, fluorescein-tagged
cHBIArah2:Arah6 was incubated with serum obtained from either a
peanut-allergic patient (serum 4) or a healthy volunteer (control). IgE-
cHBI binding was determined using ELISA by incubating cHBI-
treated serum on anti-human IgE-coated plates. The fluorescein-
tagged cHBIArah2:Arah6 showed significantly higher conjugation to IgE
in peanut-allergic patient serum than to control serum (Fig. 2A, P <
0.05). In a separate ELISA experiment, we incubated cHBIArah 2/ep5
or a cHBI presenting a Scrambled peptide (cHBIScrambled) with
patient serum, incubated on anti-human IgE-coated plates and
performed an ELISA to observe IgE binding to Ara h 2. Our
results demonstrated a significant drop in Ara h 2 binding when
serum was incubated with cHBIArah2/ep5, but not when incubated
with cHBIScrambled (Fig. 2B). Furthermore, we performed an ELISA
Table 1. Identification of the immunogenic epitopes from Ara h 2 and Ara h 6 by nanoallergen analysis
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to demonstrate that cHBIs do not nonspecifically label BSA pro-
tein and that the cHBI design is highly antigen specific (SI Ap-
pendix, Fig. S7). These results demonstrate that cHBIArah2/ep5
targeted sIgEs for Ara h 2 in an epitope-specific fashion.
Assessment of cHBI Toxicity in Vivo. To evaluate the therapeutic
potential of cHBI, next, we assessed cHBI toxicity in vivo using
C57BL/6J mice. Acute and chronic systemic toxicity of cHBIs
was assessed 3 d and 14 d post single i.v. injection of cHBIArah2:
Arah6 at 0.1, 1, and 3 mg/kg. The doses of cHBIArah2:Arah6 were
selected based on our earlier studies (23). PBS injection was used
as control. Body weight was monitored every 2–3 d for 14 d and
did not significantly vary from control (Fig. 2C). Mice were killed
at 3 and 14 d after cHBIArah2:Arah6 injection, and organ weight
and blood counts were analyzed. There was no change in liver,
kidney, spleen, heart, lung, or brain organ weights at 3 (Fig. 2D)
or 14 d (Fig. 2E) postinjection. The WBC, RBC, and platelet
counts were also unchanged (SI Appendix, Fig. S8). Based on
these results, cHBIs did not demonstrate any significant toxicity in
vivo, and therefore is likely to be well tolerated in a clinical
setting.
cHBIs Prevent Cellular Degranulation Induced by Crude Peanut Extract
in Cellular Assays Performed with Patient Serum. To further evaluate
the therapeutic potential of cHBIs, we tested if cHBIs could in-
hibit degranulation induced by peanut allergen using cells primed
with allergic patient serum. In this experiment, we primed RBL-
SX38 cells with patient serum, incubated them with cHBIArah2/ep5
or cHBIArah2:Arah6, and then challenged cells with (i) nano-
allergens, (ii) Ara h proteins, or (iii) crude peanut extract.
For nanoallergen challenge, primed RBL-SX38 cells were in-
cubated with varying concentrations (0–1,000 nM) of cHBIArah2/ep5
overnight, washed, and challenged with 1–1,000 nM of nano-
allergens presenting Ara h 2 epitope 5 (NanoallergenArah2/ep5). We
observed >95% inhibition for all cHBIArah2/ep5 concentrations
tested (SI Appendix, Fig. S9A), confirming that cHBIArah2/ep5 ef-
fectively inhibit degranulation triggered by Ara h 2 epitope 5. We
also observed that cHBIArah2/ep5 inhibited degranulation triggered
by a nanoallergen loaded with a homologous epitope from Ara h 6
(NanoallergenAra h 6/YDSYDIR, see SI Appendix, Fig. S9B).
For the purified component allergen challenge experiments,
primed RBL-SX38 cells were incubated overnight with varying
concentrations (0–2,000 nM) of cHBIArah2:Arah6, washed, and
challenged with one of the major peanut allergen proteins: Ara h 2
(10 nM), Ara h 6 (10 nM), Ara h 1 (100 nM), or Ara h 3 (100 nM)
(SI Appendix, Fig. S10). cHBIArah2:Arah6 inhibited >90% of the de-
granulation triggered by Ara h 2 or Ara h 6 for all sera tested. In
addition, cHBIArah2:Arah6 inhibited between 40% and 80% of the
degranulation triggered by Ara h 1 and Ara h 3, suggesting that
cHBIArah2:Arah6 inhibits sIgEs for Ara h 1 and Ara h 3 via epitope
cross-reactivity. In an additional control experiment, we also tested
the selectivity of cHBIArah2:Arah6 for peanut sIgEs by using the RBL-
2H3 cell line. RBL-2H3 were primed with antidinitrophenol
(DNP)-IgE, and challenged with DNP-conjugated (∼17 DNP con-
jugations per BSA) BSA (DNP-BSA) in the presence or absence of
cHBIArah2:Arah6. As expected, cHBIArah2:Arah6 did not inhibit de-
granulation induced by DNP-BSA, demonstrating that cHBIs are
allergen-selective inhibitors (SI Appendix, Fig. S11).
For the crude peanut-extract challenge, primed RBL-SX38
cells were incubated with 1 μM cHBIArah2:Arah6 overnight, washed,
and then challenged with 1–1,000 ng/mL of crude peanut extract.
Table 2. Chemical structures of cHBI inhibitors used in this study
erutcurtS dnuopmoC m/z (Da) 
cHBIAra h 2/ep5 2915.43 
cHBIAra h 6/ep5 2268.16 
FITC- 
cHBIAra h 2/ep5
3560.66 
FITC- 
cHBIAra h 6/ep5
2913.39 
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cHBIArah2:Arah6 inhibited >80% of degranulation in 14 of 16 sera
for at least one of the peanut-extract concentrations tested. Note
that due to varying levels of sensitivity of the individual subjects,
some patients had lower inhibition at higher allergen concentra-
tions (Fig. 3A and SI Appendix, Figs. S12 and S13). In control
experiments performed using either cHBIArah2/ep5 or cHBIArah6/ep5
alone, we observed <30% inhibition, demonstrating that effec-
tive inhibition required a combination of more than one immu-
nodominant epitope (SI Appendix, Fig. S14A). Western blot analysis
revealed that cHBIArah2:Arah6 suppressed crude peanut extract-
induced phosphorylation of intracellular proteins associated with
degranulation response (SI Appendix, Fig. S14B). This inhibition
was also long lasting as primed RBL-SX38 cells incubated with
cHBIArah2:Arah6 retained resistance to crude peanut extract-induced
degranulation even when challenged 3 d after cHBIArah2:Arah6 was
washed away (SI Appendix, Fig. S15). Additionally, inhibition via
cHBIArah2:Arah6 was concentration and time dependent; more
inhibition occurred at increased concentrations and incuba-
tion times (Fig. 3B). Taken together, these results demon-
strate a combination of just two engineered epitope inhibitors,
cHBIArah2:Arah6 deliver potent inhibition of immune cell and pea-
nut allergen interactions.
cHBIs Prevent Cellular Degranulation Induced by Crude Peanut
Extract in a Basophil Activation Test. Finally, to test the potential
for a clinical evaluation of the inhibitors, we evaluated cHBIs by
using a basophil activation test (BAT). The BAT is a physio-
logically relevant assay in which whole blood is taken from a
patient, incubated briefly with an allergen, and the allergic re-
sponse is monitored via flow cytometry by measuring cellular
markers of activation and degranulation, including CD63,
CD107a, or CD203c (30). Whole blood drawn in heparin vacu-
tainer tubes was taken from a single patient with a history of
severe allergic reactions to peanuts, incubated with cHBIArah2:Arah6,
challenged with 100 ng/mL crude peanut extract, and analyzed
with BAT. The percent of cells expressing CD63 above a
threshold value [CD63+, threshold shown via black line at 2 ×
104 mean fluorescence intensity (MFI)] increased from 1.4% to
70% when blood was challenged with crude peanut extract in the
absence of cHBIArah2:Arah6 inhibitors (Fig. 3C). When the blood
was treated with cHBIArah2:Arah6, however, CD63+ cells de-
creased from 70% to 16–23% (Fig. 3C). In parallel, the percent
maximal MFI of CD63 decreased when blood was treated with
0.4 and 2 μM of cHBIArah2:Arah6 (to 44% and 40% of maximal
response respectively, Fig. 3D, P < 0.05). As a control, we took
the epitope sequences in cHBIArah2:Arah6, synthesized cHBIs
presenting Scrambled epitopes of Ara h 2 epitope 5 and Ara h
6 epitope 5, and mixed them at a 1:1 ratio (cHBIScrambled).
cHBIScrambled did not reduce the levels of CD63 expression on
basophils after crude peanut extract challenge, demonstrating
that cHBIs have high selectivity (Fig. 3 C and D). In addition
to CD63, cHBIArah2:Arah6 treatment reduced the levels of
other markers of degranulation, such as CD107a and CD203c
(SI Appendix, Fig. S16). Among these markers, CD63 expression in
particular has been shown to be a predictive marker of physio-
logical severity of an allergic response (31). To further validate
these inhibitors, we performed the BAT assay on three additional
allergic patients and two nonallergic control patients (Fig. 3E and
SI Appendix, Fig. S17). There was a significant drop in CD63 and
CD107a expression when patient samples were treated with 1 μM
cHBIArah2:Arah6, while the nonallergic patients had no significant
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change in CD63 or CD107a expression. In particular, the sig-
nificant reduction in the number of CD63+ cells in allergen-
challenged cells when treated with cHBIArah2:Arah6 demonstrate
the clinical potential for cHBIs to prevent severe allergic reac-
tions to peanuts. Combined, these results demonstrate that cHBIs
have promising clinical potential to prevent allergic reactions to
peanuts and improve patient outcomes; nevertheless, studies
with larger patient populations are required to further validate
these claims.
Discussion
Here, we described the design and evaluation of cHBIs, a se-
lective sIgE inhibitor, to target and permanently inhibit the an-
tigen binding site of allergen-specific IgE antibodies that recognize
specific allergen epitope sequences. The most critical component
of cHBI design required the identification of the immunodominant
epitopes that are critical mediators during the initiation of de-
granulation responses. Using the nanoallergen platform, we
identified these immunodominant peanut-allergen epitopes for
Fig. 3. cHBIs inhibit degranulation induced by crude peanut extract in clinical patient samples. (A) cHBIArah2:Arah6 inhibits degranulation induced by crude
peanut extract. A total of 1 μM cHBIArah2:Arah6 inhibited degranulation induced by crude peanut extract in RBL-SX38 cells primed with 16 different patient
sera. Note that due to differences in patient sensitivity to crude peanut extract, patient samples were challenged with varying amount of crude peanut
extract after cHBI incubation. Patients 1, 2, and 4 were challenged with 1 μg/mL peanut extract, patients 3 and 7 with 100 ng/mL, patient 5 with 10 ng/mL, and
all others with 1 ng/mL PBS, used as a control. (B) RBL-SX38 cells primed with patient serum (serum 4) were incubated with varying concentration of cHBIArah2:Arah6
for varying time points (10 min, 30 min, 2 h, 5 h, and 16 h), washed, and then challenged with 100 ng/mL of crude peanut extract. (C ) cHBIArah2:Arah6
inhibits degranulation in BAT. BAT data for whole blood incubated with 0 μM (pink), 0.1 μM (blue), 0.4 μM (red), or 2 μM (green) cHBIArah2:Arah6 and then
challenged with 100 ng/mL crude peanut extract are shown. Flow cytometry plots are shown with fluorescence intensity on the x axis and number of basophils
on the y axis. Controls include blood incubated without crude peanut extract (no treatment), and blood incubated with 2 μM of a 1:1 mixture of cHBIs
presenting Scrambled sequences of Ara h 2 epitope 5 and Ara h 6 epitope 5, respectively (cHBIScrambled). Basophils were considered CD63 positive if fluo-
rescence intensity was greater than the threshold of 2 × 104 (black line). Percent activated basophils is shown on Right side of plot. (D) Percent maximal MFI of
flow cytometry plots from D is shown, calculated as percentage between the “0 μM” and “no stimulation” MFI values. Error bars indicate ± SD of triplicate
experiments. (E) Three additional patients were assessed using BAT assay. Whole blood from three patients was incubated with (triangles) or without
(squares) 1 μM cHBIArah2:Arah6 and then challenged with 100 ng/mL of crude peanut extract. Percent maximal MFI was similarly calculated as in D. Each point
represents an average of three technical replicates of each patient; horizontal lines represent mean of all three patients. *P < 0.05.
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a diverse set of serum samples in a functional cellular degranu-
lation assay. The results showed that the immunodominant epi-
topes were commonly shared by all of the 16 subjects. Therefore,
two cHBI molecules to mimic these two epitopes were synthesized
and evaluated.
One of the most significant and surprising results was that two
cHBIs, targeting only two of the peanut epitopes, was sufficient
to inhibit degranulation responses to crude peanut extract with
over 80% efficiency in 14 of 16 patient samples, although this
effect was dependent upon the concentration of allergen chal-
lenge. Given that patients generate IgE to multiple proteins and
multiple epitopes within each protein, the inhibition of responses
by only two epitopes highlights that we still know very little about
engagement of IgE by complex allergens. In our previous work
we demonstrated that low-affinity epitopes can cooperate with
high-affinity epitopes in IgE engagement and degranulation re-
sponses (32). Moreover, we previously observed that certain
peanut epitopes trigger degranulation at significantly lower
concentrations of nanoallergens, but when used in combination
with an epitope of lower potency, there is a synergistic en-
hancement of degranulation (12). This combinatorial aspect is
important and contrasts with many studies that use “allergens”
with high numbers of multimerized epitopes. This work suggests
several things that are important in considering allergen re-
activity. First, we suggest that there are public epitopes, reactivity
that is shared across a broad portion of the peanut-allergic hu-
man population, in IgE recognition of peanut proteins. Second,
we suggest that these public allergen epitopes are required for
allergen responses and can be therapeutically targeted to inhibit
responses. This finding potentially eliminates a major obstacle in
designing allergen-specific inhibitors, suggesting that inhibitors
would not need to be personalized and that common reagents
could be used by a broader segment of the peanut-allergic
population than initially perceived. This will be a critical con-
cept to explore in other allergens to determine if our approach to
inhibitor generation can be broadly applied to allergy treatment.
The second most significant result is increase in efficacy and the
lack of complications or off-target effects due to incorporation of
ITC in the cHBI design. From our experience with allergen model
systems, we predicted that without a permanent covalent linkage,
the epitope mimics would be unlikely to sufficiently inhibit sIgEs
due to the short half-life of peptide-based therapeutics and the
eventual dissociation of the inhibitor from sIgEs (33). One major
concern is that cHBIs will indiscriminately conjugate proteins and
trigger nonspecific inflammatory responses or side effects. While we
did not observe any acute toxicity in our mouse experiments and
have demonstrated that these inhibitors are very selective in vitro,
further studies concerning the chronic toxicology of these inhibitors
on immune responses is necessary. Based on the data from this
study, we expect cHBIs to be nontoxic and the irreversible action of
cHBI inhibitors could potentially yield long-lasting inhibition, since
IgE bound to mast cells and basophils can remain in the body for
months (34).
The cHBI design would be a significant improvement over
current allergy therapeutics. Drugs that are currently available,
such as epinephrine or antihistamines, only transiently attenuate
the intensity of the degranulation response and allergic symp-
toms. This type of approach to immune inhibition is nonspecific
and results in blocking immune components that could be im-
portant for antipathogen or antitumor immunity. Attempts at
developing specific allergy inhibitors have not been successful
due to the complexity of the immune response and the chal-
lenges arising from the multivalent nature of the interactions.
This study describes the cHBI design, which provides a solu-
tion to these issues by using a lesser-known binding site on the
Fab arm of antibodies with a multivalent design, and presents a
successful example of a specific allergy inhibitor to be used on a
clinically relevant protein-based allergen.
Materials and Methods
Materials. NovaPEG Rink amide resin, 5(6)-carboxy-fluorescein, 2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate (HBTU),
Fmoc-Lys(IvDde)-OH, all Fmoc protected amino acids, and 10 kDa 0.5 mL
centrifugal filters were purchased from EMD Millipore.
N,N-dimethylformamide (DMF) (>99.8%), dichloromethane (DCM) (>99.8%),
N,N-diisopropylethylamine (DIEA), methanol, hydrazine, piperidine, trifluoro-
acetic acid (TFA), triisopropylsilane (TIS), tryptamine, 2-naphthaleneacetic
acid, ethylene diamine, biotin, di-tert-butyl carbonate (BOC2O), 4-(dime-
thylamino)pyridine (DMAP), succinic anhydride, carbon disulfide (CS2), dii-
sopropylazocarboxylate (DIAD), 2,4-dinitro-1-fluorobenzene (DNFB), acetonitrile,
acetic acid, methanol, carbonate-bicarbonate buffer, Tween 20, indole-3-
butyric acid (IBA), biotin, PBS, streptavidin conjugated to HRP (Step- HRP),
defattened peanut meal (crude peanut extract), carboxyfluorescein (CF), and
cytochalasin D were purchased from Sigma-Aldrich. IBA-Boc is a Boc protected
variant of IBA, which was synthesized separately in house.
Ara h 1, Ara h 2, biotin-Ara h 2, Ara h 3, and Ara h 6 proteins were
purchased from Indoors Biotechnologies.
DSPC, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy
(polyethylene glycol)-2000] (DSPE-mPEG2000) (ammonium salt), mem-
branes, and all mini extruder components were purchased from Avanti Polar
Lipids (Alabaster).
High-binding and non-binding 96-well plates were purchased from
Corning. RPMI media, minimum essential media, penicillin-strep solution,
L-glutamine, and Amplex Red ELISA kits were purchased from Life Tech-
nologies. BSA, G418 disulfide salt, and FBS were purchased from Gemini
Biosciences. The 96-well tissue culture plates were purchased from Falcon.
Fmoc-N-amido-dPEG2-acid (EG2), Fmoc-N-amido-dPEG4-acid (EG4) and
Fmoc-N-amido-dPEG8-acid (EG8) were purchased from Quanta Biodesign. Fluo-
rescein isothiocyanate (FITC) was purchased from Toronto Research Chemistry.
Anti-human cyclinA IgEs (clone BF683) were purchased from BD Biosciences.
Mouse IgGPenicillin (monoclonal antibody clone P2B9) anti-human IgE (clone XTE4)
was purchased from Abcam anti-DNP IgE (clone SPE-7) was purchased from
Sigma-Aldrich. Anti-FITC mouse IgG-HRP conjugate was purchased from Jackson
Immunoresearch. All antibodies used for BAT (visibility dye, anti-HLA-DR, anti-
CD123, anti- CD63, anti-CD107a and anti-CD203c) were purchased from Fisher.
ACK lysis buffer was purchased from Lonza.
Human serum was obtained from two different sources. Peanut-allergic
patient serum (sera 1, 2, 3, and 4) and healthy nonallergic control patient
serumwere purchased from Plasma Lab International. Sera 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15, and 16 were taken from patients enrolled in an oral peanut
immunotherapy (OIT) clinical trial administered at Massachusetts General
Hospital under the direction of Wayne Shreffler (NCT01324401). Samples
were obtained from patients before OIT and selected from patients having
sIgEs for peanuts >50 kU/L as determined by ImmunoCAP.
Blood from human subjects was obtained by venipuncture from patients
with a clinical history of severe allergic reactions to peanuts or from healthy
volunteers. All volunteers consented and all studies were approved by either
theMassachusetts General Hospital Institutional Review Board or the Indiana
University Institutional Review Board.
Methods.
Nanoallergen synthesis and characterization. We utilized the epitope-lipid syn-
thesis strategy as seen in previous publications (12). We synthesized epitope-
lipids of all five Ara h 2 epitopes and five Ara h 6 epitopes using standard
Fmoc solid-phase peptide synthesis (SPPS) chemistry on NovaPEG Rink amide
resin. Residues were activated with HBTU and DIEA in DMF for 5 min and
allowed to couple to resin for 30–45 min. Coupling efficiency was monitored
using a Kaiser test. The Fmoc-protected residues were deprotected with a
3-min application of piperidine in DMF three times. After synthesis of epi-
tope as a linear peptide, an EG2 spacer, three lysines, three additional EG6
spacers, a tryptophan residue, an Fmoc-Lys(Fmoc)-OH and palmitic acid (C16)
tails were added in that order to the resin. Molecules were cleaved from the
resin using a 95/2.5/2.5 TFA/water/TIS mixture for two cycles for 45 min each.
We purified the molecules using RP-HPLC on an Agilent 1200 series system
with a semipreparative Zorbax C18 column or Zorbax C3 column with either
acetonitrile or 2-propanol gradients in the mobile phase. We monitored the
column eluent with a diode array detector allowing a spectrum from 200 to
400 nm to be analyzed. The purified product was characterized using a
Bruker Autoflex III Smartbeam matrix-assisted laser desorption ionization
time-of-flight mass spectrometer. Liposomal nanoallergens were prepared
using a procedure as previously described (35). Epitope lipids were then in-
corporated into liposomes using dry film hydration and extrusion. The li-
posomes were composed of 2% epitope lipid, 5% polyethylene glycol 2000
(mPEG2000)–DSPE, 5% cholesterol, and 93% DSPC. The lipid mixture was
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dissolved in chloroform, dried with nitrogen lyophilized for 30 min, rehy-
drated in PBS at 60 °C, and then extruded through a 100-nm polycarbonate
filter (Avanti).
The liposomes were characterized by DLS analysis via a 90Plus nanoparticle
size analyzer (Brookhaven Instruments Corp.), using 658 nm light observed at
a fixed angle of 90° at 20 °C. All nanoallergens had particle sizing between
115 and 125 nm, depending on the epitope lipid (Fig. 2C and SI Appendix).
cHBI synthesis. All inhibitors (cHBI and FITC-cHBI) were synthesized using SPPS
(23), with several modifications. First, the epitope was synthesized as a linear
peptide using Fmoc-amino acids activated with a 3.6-fold excess of HBTU
with 20-fold DIEA for 5 min before addition. Note that for FITC-cHBI, before
epitope synthesis, Fmoc-Lys-IvDdE-OH was added, then deprotected and
Fmoc-EG2-OH was added. The Fmoc was deprotected and a HBTU-activated
CF was added. Then the IvDdE group was deprotected with 2% hydrazine in
DMF and epitope synthesis was performed.
Following epitope synthesis for all cHBIs, a Fmoc-EG8-OH spacer was
added, followed by conjugation of Fmoc-Lys(IvDdE)-OH. To the Fmoc-
protected amine, IBA-BOC was added. Following IBA-Boc addition, the
IvDdE group of lysine was deprotected using 2% hydrazine in DMF in the
same fashion. Fmoc-EG4-OH spacer was added to the e-amine of this lysine.
After deprotection of the Fmoc group of the EG4 spacer, ITC domain was
added, just before cleavage from resin. The deprotected amines were
chemically modified into ITC moieties using a modified procedure from
Munch et al. (36). Briefly, resins with deprotected primary amines were
washed in anhydrous DMF three times. A 10-fold excess CS2 with a 20-fold
excess of DIEA was added in DMF and allowed to react for 30 min. Resin was
then drained and washed once with anhydrous DMF. One milliliter of DMF
with a 20-fold excess of DIEA was added to resin and cooled to ∼0 °C in
a −20 °C freezer. Then, a 2-fold excess of Boc2O and 0.2-fold of DMAP was
added to the vessel and allowed to react for 20 min at −20 °C. The vessel
was removed, allowed to warm to room temperature for 30 min, and then
washed with DMF, DCM, and diethyl ether and allowed to dry in a vacuum
chamber. See SI Appendix, Fig. S5 for further details.
Molecules were cleaved from the resin using a 95/2.5/2.5 TFA/water/TIS
mixture for two cycles for 45 min each. The resulting solution was evaporated
using a Buchi rotor-evaporator to remove TFA, rehydrated in 50/50 ACN/
water, and purified by RP-HPLC using an Agilent 1200 series HPLC with a
Zorbax C18 semiprep column using an ACN/water gradient between 20% and
60% ACN in 10 min with a flow rate of 4 mL/min. Product was collected,
evaporated, lyophilized, and redissolved in DMSO. Concentration was de-
termined by absorbance at 280 nm or 335 nm. All molecules were charac-
terized using high-resolutionMicroTOFMS analysis. Purity was determined by
analytical RP-HPLC using Zorbax Eclipse XBD-C18 with a 20–60% ACN gra-
dient; all molecules were assessed to have >95% purity through analysis of a
220-nm signal.
The following molecules used in this study were analyzed using high-
resolution mass spectroscopy using a Bruker microTOF II mass spectrome-
ter. Note that all molecular weights have +1 mass increase from the addition
of a proton. cHBIArah2/ep5 (C126H207N27O49S) was determined to be 2916.45m/z
(2915.43m/z expected); cHBIArah6/ep5 (C99H170N18O39S) was determined to be
2269.17m/z (2268.16m/z expected); FITC-cHBIArah2/ep5 (C160H242N30O59S) was
determined to be 3561.67 m/z (3560.66 m/z expected); and FITC-FITC-
cHBIArah6/ep5 (C133H205N21O49S) was determined to be 2914.40 m/z (2913.39
m/z expected).
Cell culture. RBL-SX38 cells (cells expressing human FceRI) were a generous gift
from Jean-Pierre Kinet, Harvard University, Cambridge, MA. RBL-SX38 were
cultured in MEM (Gibco) with 10% FBS (Gemini BioProducts), l-glutamine,
penicillin-streptomycin, and 1.2 mg/mL of G418 salt (Sigma) as previously
described (37). RBL-2H3 cells (ATCC) were cultured in a similar manner but
without the addition of G418.
Degranulation assays. Degranulation assays were performed as previously
described using nanoallergens, Ara h proteins, or crude peanut extract as the
allergen with some modifications (12). RBL-SX38 cells were plated (100 μL
each, 50,000 cells per well) into 96-well dishes for 24 h and then incubated
with 10% of patient sera (sera 1–16 or a serum taken from healthy volunteer
as control) in cell culture media for an additional 24 h before the de-
granulation assay. Cells were then washed and incubated in RBL media for
1 h. Cells were then washed, incubated in tyrodes buffer with 0.5 mg/mL BSA
and 1 μM Cytochalasin D, and challenged with allergens or lysed with Triton
X (as a positive control). After allergen challenge, the supernatant was in-
cubated with pNAG solution for 45 min, the reaction halted with a stopping
solution (1.5 mg/mL glycine, pH 10.7), and the degranulation measured by
reading the absorbance at 405 nm after subtracting the background signal
at 630 nm.
To evaluate the cHBI inhibitors, RBL-SX38 cells were similarly plated and
primed with patient serum. However, before incubation with allergen, cells
were incubated with cHBIs (15 min–24 h), and similarly challenged with al-
lergens as described above. Note that concentrations of crude peanut ex-
tract used for inhibition assays shown in Fig. 3A varied, given the
sensitization of the patient to crude peanut extract. A total of 1 ng/mL was
used for serum 6 and sera 8–16, 100 ng/mL was used for sera 3 and 7, and the
remaining sera 1, 2, and 4 were challenged with 1,000 ng/mL.
For DNP-BSA degranulation assays, a similar procedure was used with the
following exceptions: RBL-2H3 cells were used instead of RBL-SX38 cells, and
cells were incubated with a 25%/75%mixture of anti-DNP IgE and anti-cyclin A
IgE for 24 h instead of patient serum, and DNP-BSA was used as the allergen.
Percent degranulation was calculated as previously decribed (32). Briefly,
experimental signals were calculated as a percentage between positive
control (100%) and negative control (0%). Degranulation maximum (Dmax)
and EC50 values were calculated using Origin 7 software using Hill’s curve fit
for sigmoidal curves using percent degranulation values. Note that if nano-
allergen did not induce significant degranulation above error (determined as
SD of triplicate experiments, P < 0.05), it was deemed to have “no response.” If
a significant signal was present but there was insufficient data to determine
an EC50 value, the EC50 value was estimated to be greater than an EC50 value
calculated assuming that the highest signal reached was Dmax.
ELISA assay. Binding interactions between cHBI and antibodies were detected
using a sandwich ELISA. Before the ELISA test, patient serumwas incubated at
various concentrations with FITC-cHBIs at 37 °C for 5 h. Then, a high-binding
96-well ELISA plate was coated with 100 μL of 2 nM of anti-IgE antibody for
2 h in bicarbonate buffer (pH = 10). Plates were washed to remove unbound
antibody. Wells were blocked with a blocking buffer (5% BSA, 0.2% Tween-
20 solution in PBS) for 1 h, washed, and incubated with serum-cHBI mixture
mixed 1:1 with the blocking buffer for 16 h. The plate was washed again and
incubated with an anti-FITC mouse IgG-HRP conjugate (diluted 1:5,000 in
blocking buffer) for 1 h. The plate was washed again and an Amplex Red Kit
was used to quantify the ELISA signal using a SpectraMax M5 spectropho-
tometer according to the manufacturer’s instructions.
For the Ara h 2 competitive binding inhibition, a similar ELISA was per-
formed with some modifications. Before the ELISA test, patient serum was
incubated in various concentrations with unlabeled cHBIs at 37 °C for 5 h.
Then, a high-binding 96-well ELISA plate was coated with 100 μL of 2 nM of
anti-IgE antibody for 2 h in bicarbonate buffer. Plates were washed with PBS
to remove unbound antibody. Wells were blocked with the blocking buffer
for 1 h, washed, and incubated with serum-cHBI mixture mixed 1:1 with the
blocking buffer for 16 h. The plate was washed again and incubated with
biotin-tagged HRP (diluted 1:5,000 in blocking buffer) for 1 h. The plate was
washed again, incubated with streptavidin-HRP conjugate, washed, and an
Amplex Red Kit was used to quantify the ELISA signal using a SpectraMax
M5 spectrophotometer according to the manufacturer’s instructions.
Animal studies. C57BL/6 female mice (7- to 8-wk old) were obtained fromHarlan
Biosciences. Mice were maintained in pathogen-free conditions, and studies
were approved by the Indiana University Institutional Animal Care and Use
Committee. Toxicology studies were carried out in a similar manner as pre-
viously published in the University of Indiana In Vivo Therapeutics Core (32).
Basophil activation test. The BAT assay protocol was used as previously de-
scribed (38). Briefly, blood collected in vacutainer tubes containing heparin
was processed within 24 h of collection. For basophil activation: 100 μL of
whole blood was diluted 1:1 in serum-free RPMI containing cHBIs for 4 h at
37 °C. Cells were activated with 100 ng/mL of crude peanut extract or media
(blank) for 30 min at 37 °C. RBs were lysed using ACK lysis buffer and
remaining cells were stained and fixed for flow cytometry. Basophils were
selected as viability dye negative, SSClow, HLA-DR−, and CD123+. Each sample
was analyzed in triplicate with a cutoff of 1,000 basophils per sample. Ba-
sophil activation was assessed by measuring fluorescence of CD63, CD107a,
and CD203c. Percentage maximal CD63 MFI was found by calculating the
percentage between the blank (negative control) and the no inhibitor
(positive control) MFI for CD63.
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